Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,371,531 shares, an increase of 25.1% from the March 31st total of 1,096,114 shares. Based on an average daily volume of 160,808 shares, the short-interest ratio is presently 8.5 days. Currently, 2.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

GLPG has been the topic of a number of research reports. UBS Group restated a “market perform” rating on shares of Galapagos in a research report on Tuesday, February 24th. Raymond James Financial reissued a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of Galapagos from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Royal Bank Of Canada boosted their price objective on shares of Galapagos from $32.00 to $33.00 and gave the company a “sector perform” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings upgraded shares of Galapagos from a “sell (d)” rating to a “hold (c)” rating in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $36.50.

Galapagos Stock Up 0.6%

NASDAQ GLPG traded up $0.17 during trading on Friday, reaching $28.00. 107,777 shares of the stock traded hands, compared to its average volume of 128,693. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -17.83 and a beta of 0.25. The stock’s 50-day moving average price is $30.81 and its 200 day moving average price is $31.97. Galapagos has a fifty-two week low of $24.74 and a fifty-two week high of $37.78.

Galapagos (NASDAQ:GLPG) last issued its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The firm had revenue of $1.06 billion for the quarter. Analysts anticipate that Galapagos will post -6.97 EPS for the current fiscal year.

Institutional Trading of Galapagos

A number of large investors have recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Galapagos during the 1st quarter worth approximately $248,000. QRG Capital Management Inc. increased its stake in Galapagos by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after purchasing an additional 3,535 shares in the last quarter. XTX Topco Ltd increased its stake in Galapagos by 92.6% during the 4th quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after purchasing an additional 11,162 shares in the last quarter. Millennium Management LLC increased its stake in Galapagos by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after purchasing an additional 186,452 shares in the last quarter. Finally, Madison Avenue Partners LP increased its stake in Galapagos by 0.8% during the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after purchasing an additional 17,394 shares in the last quarter. 32.46% of the stock is owned by institutional investors.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.